Zihipp

Zihipp Limited is a biotechnology company based in London, United Kingdom, that specializes in developing peptide hormones for the treatment of diabetes and obesity. Founded in 2012, Zihipp focuses on creating novel weight loss therapies that target metabolic disorders through analogs of key satiety hormones, such as oxyntomodulin and PYY peptides. By optimizing potency and extending the half-lives of these peptides, Zihipp aims to provide effective solutions for the growing pandemics of obesity and diabetes, ultimately helping doctors offer patients sustainable weight management options. The company’s innovative approach addresses the urgent need for effective treatments in the realm of metabolic health.